Similarly, in vivo results show that the overexpression of IRF9 or STAT2 delays vemurafenib-induced tumor regression, whereas knockdown of IRF9 or STAT2 potentiates tumor growth inhibition. This evidence concerns the gene STAT2 and neoplasm.